Site-directed mutagenesis modified glycoprotein hormones
US5260421A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 21, 1987 |
| Grant date | Nov 9, 1993 |
| Priority date | — |
| Expiry date | Dec 21, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.